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Abstract
Since the Gbc subunit of Gi protein has been importantly implicated in regulating immune and inflammatory responses, this
study investigated the potential role and mechanism of action of Gbc signaling in regulating the induction of airway
hyperresponsiveness (AHR) in a rabbit model of allergic asthma. Relative to non-sensitized animals, OVA-sensitized rabbits
challenged with inhaled OVA exhibited AHR, lung inflammation, elevated BAL levels of IL-13, and increased airway
phosphodiesterase-4 (PDE4) activity. These proasthmatic responses were suppressed by pretreatment with an inhaled
membrane-permeable anti-Gbc blocking peptide, similar to the suppressive effect of glucocorticoid pretreatment. Extended
mechanistic studies demonstrated that: 1) corresponding proasthmatic changes in contractility exhibited in isolated airway
smooth muscle (ASM) sensitized with serum from OVA-sensitized+challenged rabbits or IL-13 were also Gbc-dependent and
mediated by MAPK-upregulated PDE4 activity; and 2) the latter was attributed to Gbc-induced direct stimulation of the non-
receptor tyrosine kinase, c-Src, resulting in downstream activation of ERK1/2 and its consequent transcriptional upregulation
of PDE4. Collectively, these data are the first to identify that a mechanism involving Gbc-induced direct activation of c-Src,
leading to ERK1/2-mediated upregulation of PDE4 activity, plays a decisive role in regulating the induction of AHR and
inflammation in a rabbit model of allergic airway disease.
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Introduction
G proteins play critical roles in regulating the allergic asthmatic
phenotype, including the induction of airway hyperresponsiveness
(AHR) and inflammation [1]. The G proteins are heterotrimers
comprised of a, b and c subunits and, upon activation by G
protein-coupled receptors (GPCRs) that respond to a host of
bronchoactive and proinflammatory stimuli, the Ga subunit
undergoes an exchange of GTP for GDP and becomes dissociated
from the Gbc subunits [2]. Both the free Ga and Gbc subunits can
then activate different effectors, importantly including those
stimulating the MAPK signaling pathways that regulate various
immune and inflammatory cell functions [3]. The MAPK
pathways are also implicated in regulating different aspects of
airway smooth muscle (ASM) function and inflammation under
proasthmatic conditions, including activation of transcription
factors and other downstream effectors that mediate the release
of proinflammatory cytokines and chemokines which can alter
ASM contractility and growth [4–6].
Previous studies demonstrated that the class of pertussis toxin
(PTX)-sensitive G proteins that inhibit adenylate cyclase activity
(i.e., Gi proteins) plays a particularly important role in mediating
the heightened agonist-induced constrictor responses and impaired
b2-adrenoceptor (b2AR)-induced relaxation responses exhibited
in isolated ASM tissues exposed to different proasthmatic
conditions, including passive sensitization with serum from atopic
asthmatic patients [7], proinflammatory cytokine exposure [8],
and inoculation with rhinovirus [9]. More recently, we reported
that PTX-sensitive proasthmatic changes in ASM responsiveness
are also exhibited in ASM tissues following their prolonged
heterologous or homologous b2AR desensitization, and that this
altered ASM function is attributed to upregulated phosphodies-
terase 4 (PDE4) activity induced by activation of the Gbc subunit
of Gi protein [10,11]. Specifically, Gbc signaling was found to
activate the non-receptor tyrosine kinase, c-Src, which stimulates
the Ras/c-Raf1/MEK signaling pathway leading to downstream
activation of the MAPK, ERK1/2, the latter evoking transcrip-
tional upregulation of PDE4 activity [10,11]. Collectively, these
findings were consistent with the prevailing concept that GPCR-
dependent and receptor-independent stimulation of Ras-mediated
ERK1/2 activation uses proximal signals generated by the bc
subunits of G protein coupled to c-Src activation [12–16]. In light
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relationship between PTX-sensitive Gbc signaling and inflamma-
tion [17–22], the present study addressed the hypothesis that Gbc
signaling regulates the altered airway responsiveness and inflam-
mation exhibited in the allergic asthmatic state. The results
obtained in studies conducted in an in vivo rabbit model of allergic
asthma and in isolated atopic sensitized ASM tissues are the first to
demonstrate that: 1) inhibition of Gbc signaling prevents the
induction of airway hyperresponsiveness and inflammation elicited
by antigen challenge in allergic rabbits, as well as the pro-
asthmatic changes in constrictor and relaxation responsiveness
exhibited in atopic sensitized ASM tissues; and 2) these
bronchoprotective actions of Gbc inhibition are attributed to
suppression of Gbc-induced direct activation of c-Src, which leads
to downstream ERK1/2-dependent upregulation of PDE4 activity
and its consequent pro-asthmatic effects on airway function.
Taken together, these new findings highlight a heretofore-
unidentified pivotal role for Gbc signaling in regulating the
airway asthmatic phenotype, and suggest that interventions
targeted at suppressing Gbc signaling associated with Gi protein
activation may lead to new approaches to treat allergic airway
disease.
Results
Gbc-coupled ERK1/2 and PDE4 activation mediates
altered constrictor and relaxation responsiveness in
atopic sensitized ASM
Given recent evidence demonstrating that transcriptional
upregulation of PDE4 activity due to Gi-bc-regulated activation
of ERK1/2 mediates proasthmatic changes in agonist responsive-
ness in b2AR-desensitized ASM [10,11,23], we initially examined
whether these signaling molecules also participate in mediating the
reported IgE-induced Gi protein-dependent proasthmatic changes
in responsiveness exhibited in ASM tissues passively sensitized with
atopic asthmatic serum [7,24]. Accordingly, agonist-induced
constrictor and relaxation responses were compared in isolated
naı ¨ve rabbit ASM tissues that were incubated overnight with
vehicle alone (control) or serum isolated from either non-sensitized
(control serum) or OVA-sensitized rabbits at 24 hr following OVA
inhalation (OVA serum), both in the absence and presence of
pretreatment with either the PDE4 inhibitor, rolipram (10 mM),
the ERK1/2 inhibitor, U0126 (5 mM), or a Gbc sequestering
(blocking) peptide (20 mM) comprised of the C-terminal domain of
phosducin-like protein (PhLP) conjugated to an inert membrane
permeable peptide (MPS) carrier [25]. The latter anti-Gbc
blocking peptide was previously shown to inhibit Gi protein-
dependent upregulation of PDE4 activity and its consequent
induction of altered responsiveness in b2AR-desensitized ASM
[11]. As shown in Fig. 1A, relative to the similar responses
obtained in vehicle- and control serum-exposed tissues, OVA
serum-sensitized ASM tissues exhibited significantly increased
constrictor responsiveness to cumulative administration of ACh,
yielding a mean 6 SD maximal constrictor response (Tmax) that
averaged 121.7616.7% of control (p,0.05). This enhanced
contractility was completely abrogated in OVA serum-sensitized
tissues that were pretreated either with the anti-Gbc blocking
peptide, rolipram, or U0126, with no significant differences
observed between the protective effects of these inhibitors.
Under the same treatment conditions, cumulative administra-
tion of the b2AR agonist, isoproterenol, produced dose-dependent
relaxation of half-maximally pre-constricted ASM segments
(Fig. 1B). Relative to controls, the relaxation responses were
significantly attenuated in the OVA serum-sensitized tissues,
wherein the mean 6 SE maximal relaxation response (Rmax)
amounted to 27.8612.1% vs. 46.1611.1% in the controls
(p,0.01). This impaired relaxant responsiveness was also ablated
in OVA serum-exposed tissues that were pretreated either with the
anti-Gbc blocking peptide, rolipram, or U0126, with no significant
differences detected between the protective effects of these
inhibitors. Of note, results obtained in related experiments
demonstrated that: 1) relative to untreated (vehicle-exposed)
tissues, neither the Tmax nor Rmax responses to ACh and
isoproterenol, respectively, were significantly affected in control
serum-exposed ASM tissues that were pretreated either with the
inert MPS carrier peptide alone or anti-Gbc blocking peptide; and
2) in contrast to the protective effects of the anti-Gbc peptide in
OVA serum-sensitized ASM tissues, pretreatment of these tissues
with MPS alone did not significantly affect their altered agonist
responsiveness (Fig. S1). Moreover, as we previously reported in
naı ¨ve rabbit ASM tissues [10,11,23], neither co-incubation with
rolipram, U0126, nor the anti-Gbc peptide significantly affected
the responsiveness of control serum-exposed ASM tissues to either
ACh or isoproterenol (data not shown). Thus, in demonstrating
that inhibition of either Gbc, ERK1/2 or PDE4 signaling prevents
the changes in agonist responsiveness elicited in OVA serum-
sensitized ASM, these observations are consistent with those
previously reported in b2AR-desensitized ASM wherein activation
of the Gbc subunit of Gi protein was also found to initiate ERK1/
2-dependent rolipram-sensitive proasthmatic changes in constric-
tor and relaxation responsiveness [10,11,23].
Gbc signaling mediates in vivo airway
hyperresponsiveness in allergic rabbits
To determine whether Gbc inhibition exerts a comparable
bronchoprotective action in vivo, we examined the effect of
pretreatment with aerosolized anti-Gbc blocking peptide on
bronchoconstrictor responsiveness to MCh in OVA-sensitized
rabbits, and compared this effect to that of the inhaled
glucocorticosteroid, budesonide. The measurements of baseline
respiratory system resistance (Rrs) obtained at 24 hr following
antigen challenge in non-sensitized (control) and OVA-sensitized
rabbits were not significantly different, averaging 0.02960.004
and 0.03160.005 cmH20/ml/sec, respectively. Relative to
controls, however, the OVA-sensitized rabbits exhibited pro-
nounced AHR to i.v. administration of MCh, as evidenced by
markedly heightened dose-dependent increases in Rrs (Fig. 2). The
mean 6 SE maximal MCh-induced increase in Rrs (Rrs-max)
averaged 7.8160.74-fold above baseline in the OVA-sensitized
rabbits vs. an increase of 3.0160.60-fold in the control animals
(p,0.001). This AHR was virtually completely suppressed in
OVA-sensitized rabbits that were treated with inhaled anti-Gbc
blocking peptide prior to OVA challenge, similar to the
suppression of AHR exhibited in OVA-sensitized rabbits that
were pretreated with inhaled budesonide (Fig. 2). Of note,
comparable significant differences were also detected when
analyzing these data using the nonparametric Kruskal-Wallis test
(p=0.023), with the Dunn’s post-test demonstrating a significant
difference (p,0.05) when comparing the median Rrs-max value in
the control (2.69; range: 2.10–4.89) vs. non-pretreated OVA
sensitized rabbits (7.29; range: 6.05–9.84), whereas no significant
difference was detected when comparing the median of the
controls vs. median Rrs-max of 3.22 (range: 6.95–9.84) obtained in
the OVA-sensitized animals that were pretreated with the anti-
Gbc blocking peptide. In relation to these observations, it should
be noted that results generated in separate experiments demon-
strated that, relative to the above corresponding determinations: 1)
bronchoconstrictor responsiveness to MCh was unaffected in
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max=2.8260.63-fold above baseline; n=3); 2) the AHR evoked
by antigen challenge was not significantly altered in OVA-
sensitized rabbits that were treated with MPS alone (i.e., Rrs-
max=6.9560.84-fold above baseline; n=3); and 3) suppression of
AHR comparable to that observed in anti-Gbc blocking peptide-
or budesonide-treated rabbits was also detected in OVA-sensitized
rabbits that were pretreated with gallein (30 mg/Kg; n=4), a
small molecule inhibitor of Gbc signaling [17,26,27], yielding Rrs-
max values of 2.5460.72-fold above baseline. Finally, in
accordance with the above observations, comparable results were
also obtained when analyzing MCh responsiveness in terms of the
corresponding changes in dynamic compliance (Cdyn) measured
under the different experimental conditions. The baseline Cdyn
values were lower in the OVA-sensitized+challenged vs. control
rabbits, averaging 3.7160.06 vs. 4.4560.04 ml/cmH20, respec-
tively (p,0.05) and, as depicted in Fig. S2: 1) relative to controls,
MCh-induced decreases in Cdyn (expressed as % of baseline) were
significantly greater in the OVA-sensitized+challenged rabbits;
and 2) this induced change in the Cdyn responses to MCh was
suppressed in OVA-sensitized rabbits that were treated with anti-
Gbc blocking peptide before antigen challenge, similar to the
suppression exhibited in OVA-sensitized rabbits that were
pretreated with budesonide. As with the above Rrs data,
Figure 1. Inhibition of ERK1/2, PDE4, or Gbc signaling prevents induced changes in agonist responsiveness in OVA-serum-
sensitized ASM tissues. Relative to vehicle- or control serum-exposed rabbit ASM tissues, tissues passively sensitized for ,18 hr with OVA serum
exhibit significantly increased contractility to ACh (A) and impaired relaxation to isoproterenol (B). Pre-treatment with either U0126, rolipram, or anti-
Gbc peptide prevents OVA serum-induced changes in ASM responsiveness. Data are mean 6 SD values from 5–7 experiments. ANOVA used for
multiple comparisons of mean Tmax values. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0032078.g001
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the nonparametric Kruskal-Wallis test and Dunn’s post-test to
compare the Cdyn responses generated in the control vs. OVA-
sensitized rabbits in the absence (p,0.05) vs. presence (p=NS) of
pretreatment with anti-Gbc blocking peptide.
Gbc signaling mediates allergic airway inflammation in
OVA-sensitized rabbits
Together with its above bronchoprotective action, inhaled
pretreatment with anti-Gbc blocking peptide also suppressed the
pulmonary inflammatory response detected in the sensitized
rabbits at 24 hr following OVA challenge. As shown by the
representative lung sections in Fig. 3, relative to control (non-
sensitized) rabbits that showed no sign of inflammation (Fig. 3A),
lungs isolated from OVA-sensitized+challenged rabbits exhibited
multiple patchy foci of peribronchial, perivascular, and parenchy-
mal inflammation (Fig. 3B). The inflammatory cell infiltrates
consisted mainly of neutrophils and, to a lesser extent, macro-
phages and rare eosinophils, as depicted in the high magnification
photomicrographs of representative lung tissue and BAL fluid
(BALF) samples in Figs. 4A and 4B, respectively. In contrast to the
lack of effect of pretreatment with MPS alone (Fig. 3C), the
inflammatory response was distinctly suppressed to a similar extent
in OVA-sensitized+challenged rabbits that were pretreated with
either inhaled budesonide or anti-Gbc blocking peptide (Figs. 3D
and 3E, respectively). Interestingly, by comparison, the inflamma-
tory response was largely unaffected in OVA-sensitized+chal-
lenged rabbits that were pretreated with gallein (Fig. 3F),
suggesting differences between this small molecule inhibitor of
Gbc and the anti-Gbc blocking peptide with respect to their anti-
inflammatory actions (see Discussion).
Comparable results were obtained with respect to the
corresponding changes in BALF cellular content and cytokine
levels. Due to variability in recovery and dilution between the
individual BALF samples, these data were analyzed with respect to
changes in inflammatory cell counts per high power field (HPF) in
BALF cytospins (Fig. 5A), wherein at least 500 cells were counted
in each cytospin preparation, and as changes in the neutrophil/
macrophage cell ratio (Fig. 5B). The box plots in Fig. 5 depict the
median and range of the values determined under each
experimental condition, and the nonparametric Kruskal-Wallis
test with Dunn’s post-test analysis demonstrated that, as compared
to non-sensitized (control) rabbits challenged with OVA, the
OVA-sensitized+challenged animals exhibited significant increases
(p,0.05) in both the total number of cells (Fig. 5A) and
neutrophil/macrophage cell ratio (Fig. 5B). Moreover, after
antigen challenge, the control vs. OVA-sensitized rabbits also
exhibited differences in their BALF levels of the signature Th1-
and Th2-type cytokines, IFN-c and IL-13, respectively. Compared
to controls, the levels of IFN-c were significantly reduced (p,0.05)
in the OVA-sensitized+challenged rabbits (Fig. 5C), whereas the
IL-13 levels (Fig. 5D) were significantly increased (p,0.05). As
further depicted, the induced changes in the above inflammatory
indices were suppressed in OVA-sensitized+challenged rabbits
that were pretreated with inhaled anti-Gbc blocking peptide, with
no sigificant differences detected when compared to the control
animals.
Gbc activation regulates PDE activity in OVA-challenged
allergic lungs and sensitized ASM tissues
Upregulated PDE4 activity was shown to play a determinant
role in mediating airway hyperresponsiveness and inflammation in
response to allergen challenge in asthmatic individuals [28] and in
animal models of allergic asthma [29–33]. Given this evidence,
together with the above data implicating an association between
Gbc activation and rolipram-sensitive proasthmatic changes in
responsiveness in OVA serum-sensitized ASM tissues (Fig. 1), we
next examined whether lung tissues isolated from OVA-sensiti-
zed+challenged rabbits and ASM tissues passively sensitized with
sera from these animals exhibit Gbc-dependent changes in cAMP
PDE activity. Relative to peripheral lung tissue sections isolated
from control rabbits, as well as sensitized rabbits that were not
challenged with OVA, significantly increased levels of PDE
activity were detected in the lung tissues of OVA-sensitized+chal-
lenged rabbits (Fig. 6A). Similarly, relative to naı ¨ve ASM tissues
exposed to control serum, significantly increased levels of PDE
activity were detected in ASM tissues that were passively sensitized
with OVA serum (Fig. 6B). This upregulated PDE activity was
abrogated in lungs from OVA-sensitized+challenged rabbits that
were pretreated in vivo with anti-Gbc blocking peptide, and the
latter pretreatment also suppressed the increased PDE activity in
OVA serum-exposed ASM tissues (Figs. 6A and 6B, respectively).
Of note, comparable results were also obtained in separate
experiments wherein naı ¨ve ASM tissues were exposed for 24 hr to
a maximally effective concentration of IL-13 (50 ng/ml) [34], the
Th2 cytokine that is critically implicated in mediating antigen-
induced airway hyperresponsiveness in vivo [35,36], as well as the
pro-asthmatic changes in contractility in atopic serum-sensitized
ASM tissues, the latter attributed to IgE-induced activation of its
low affinity receptor (CD23) [24,34]. As shown in Fig. 6C, relative
to controls, IL-13-treated ASM tissues exhibited significantly
increased PDE activity that was suppressed by pretreatment with
either the anti-Gbc blocking peptide or gallein (10 mM).
Figure 2. Anti-Gbc blocking peptide prevents in vivo antigen-
induced airway hyperresponsiveness in OVA-sensitized rab-
bits. Relative to OVA-challenged control (non-sensitized; n=4) rabbits,
Rrs responses to MCh are significantly increased at 24 hr following
antigen challenge in OVA-sensitized rabbits (n=4). This heightened
bronchoconstrictor responsiveness to MCh is suppressed in OVA-
sensitized rabbits that are treated either with inhaled anti-Gbc peptide
(1 mg/Kg; n-=4) or budesonide (0.5 mg/Kg; n=3) prior to antigen
challenge. Data are mean 6 SE values. ANOVA used for multiple
comparisons of mean Rrs values. *p,0.05; **p,0.01. Note: a significant
difference is also detected when using the nonparametric Kruskal-Wallis
test with Dunn’s post-test to compare the medians of the Rrs-max
responses in the control vs. non-pretreated OVA sensitized rabbits
(p,0.05), whereas no significant difference is detected between the
control vs. OVA-sensitized animals that are pretreated with the anti-Gbc
blocking peptide.
doi:10.1371/journal.pone.0032078.g002
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exposed human ASM cells
Since signaling initiated by Gi-bc was found to mediate ERK1/
2-dependent PDE4-induced proasthmatic changes in responsive-
ness in b2AR-desensitized rabbit ASM tissues and cultured human
ASM (HASM) cells [10,11,23], a series of studies were pursued to
systematically evaluate the role of this signaling mechanism in
regulating ASM function under the present conditions of ASM
sensitization. We initially examined whether HASM cells treated
with IL-13 exhibit Gbc-regulated c-Src and ERK1/2 activation,
and whether this phenomenon is attributed to direct protein-
protein interaction between activated Gbc and c-Src. Accordingly,
the effects of Gbc inhibition on IL-13-induced phosphorylation of
c-Src protein at residue Tyr416, which denotes the activated
autophosphorylated state of the kinase [37], and ERK1/2 were
assessed using phospho-c-Src
Tyr416- and phospho-ERK1/2-specif-
ic antibodies. Corresponding total levels of c-Src and ERK1/2
were also determined in the same immunoblot preparations by
stripping the membranes and reincubating with anti-c-Src and -
ERK1/2 antibodies. Treatment of HASM cells with IL-13
(50 ng/ml) elicited temporal increases in both c-Src
Tyr416 and
ERK1/2 phosphorylation that peaked at 10 and 30 min,
respectively (Fig. 7A). As demonstrated in Fig. 7B, contrasting
the lack of effect of pretreatment with the inert MPS peptide alone
(20 mM), peak IL-13-induced phosphorylation of both c-Src
Tyr416
and ERK1/2 was suppressed in HASM cells pretreated with
maximally effective concentrations of either anti-Gbc blocking
peptide (20 mM) or gallein (10 mM). Similar results were also
obtained when comparing the effects of IL-13 on c-Src
Tyr416 and
ERK1/2 phosphorylation in HASM cells at 24 hr following
transfection with either an adenovirus vector expressing lacZ
(adeno-LacZ), serving as a negative control, or adeno-bARK-ct,
Figure 3. Anti-Gbc blocking peptide suppresses pulmonary inflammation in OVA-sensitized rabbits. Relative to controls (A), lungs
isolated from antigen-challenged OVA-sensitized rabbits exhibit diffusely scattered patchy foci of inflammatory cell infiltration, including in
peribronchial, perivascular, and parenchymal regions (B). Contrasting the lack of effect of pretreatment with MPS alone (C), inflammation is
suppressed to a similar extent in antigen-challenged OVA-sensitized rabbits that were pretreated either with inhaled budesonide (D) or anti-Gbc
peptide (E), whereas pretreatment with gallein has relatively little anti-inflammatory effect (F). Representative photomicrographs (mag. 6100) are
from 4 mM sections of H&E stained lung sections.
doi:10.1371/journal.pone.0032078.g003
G Protein bc-Subunit Signaling in Asthma
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32078which encodes the C-terminal domain of bARK1 that was shown
to block Gbc signaling [14,15], both at a multiplicity of infection
(MOI) of 100. Whereas cells transfected with adeno-LacZ
exhibited IL-13-induced c-Src
Tyr416 and ERK1/2 phosphoryla-
tion, this effect of IL-13 was prevented in cells transfected with
adeno-bARK-ct (Fig. 7B).
In light of the above results implicating Gbc as an upstream
regulator of IL-13-induced c-Src activation, co-immunoprecipita-
tion studies were then conducted to determine whether IL-13
evokes a direct interaction between activated Gbc and phosphor-
ylated c-Src. The immunoblots in Fig. 7C demonstrate that,
relative to unstimulated cells, enhanced co-localization of
phosphorylated c-Src
Tyr416 with immunoprecipitated Gb was
detected in IL-13-treated HASM cells (Fig. 7C; top panel), and
that this induced association was abrogated in IL-13-exposed
HASM cells that were pretreated with either anti-Gbc blocking
peptide or gallein, as well as in IL-13-exposed cells that were
transfected with adeno-bARK-ct. Of note, these results were
obtained under similar conditions of loading of immunoprecipi-
tated Gb, as evidenced by the immunoblots using anti-Gb
antibody in Fig. 7C (bottom panel). Thus, together with the
above observations, these data support the concept that IL-13
stimulates direct coupling of activated Gbc to c-Src, and that this
signaling event is associated with ERK1/2 activation in the
cytokine-exposed ASM.
Gbc regulates IL-13-induced transcriptional upregulation
of PDE4: Role in mediating altered ASM responsiveness
To further elucidate the mechanism by which Gbc regulates the
induction of PDE4 activity, we next investigated the effects of
inhibition of Gbc signaling and its suspected downstream effectors
on IL-13-induced PDE4 expression in HASM cells. As shown in
Fig. 8A, treatment of HASM cells with IL-13 (50 ng/ml624 hr)
evoked temporal increases in mRNA expression of PDE4D, the
functionally dominant PDE4 subclass in HASM cells [38,39], with
peak expression detected at 12 hr and elevated levels sustained at
24 hr. As demonstrated by a representative experiment in Fig. 8B,
and the corresponding results based on densitometric analysis of
the data obtained in 4 such experiments in Fig. 8C, relative to
control (vehicle-exposed) HASM cells (lane 1), IL-13-induced
upregulation of PDE4D transcripts at 12 hr averaged ,7.6-fold
(lane 2), and this response was suppressed by pretreating IL-13-
exposed cells with previously reported [10,11,23] maximally
effective concentrations of either PTX (100 ng/ml; lane 3), which
ADP ribosylates Gi protein, the anti-Gbc blocking peptide
(20 mM; lane 4), or the ERK1/2 inhibitor, U0126 (5 mM; lane 5).
By comparison, induction of PDE4D transcripts by IL-13 was
unaltered in cells pretreated with either the p38 MAPK inhibitor,
SB202190 (10 mM; lane 6) or the JNK inhibitor, SP600125
(10 mM; lane 7), whereas the induction of PDE4D5 transcripts was
prevented in IL-13-exposed cells that were pretreated with either
the c-Src family tyrosine kinase inhibitor, SU6656 (10 mM; lane 8)
or gallein (10 mM, lane 9). Thus, consistent with earlier evidence
demonstrating that activation of the Gbc subunit of Gi protein
elicits c-Src-induced downstream signaling via the Ras/c-Raf1/
MEK-ERK1/2 pathway [14,15], the above results support the
notion that IL-13-induced PDE4 expression is regulated by Gi-bc
signaling coupled to c-Src activation that, in turn, leads to
downstream ERK1/2-dependent induction of PDE4D transcripts.
In concert with the above results, extended studies conducted in
isolated rabbit ASM tissues demonstrated that (Fig. 9): 1) as
previously described [34], relative to controls, ASM tissues
exposed to IL-13 (50 ng/ml624 hr) exhibit significantly height-
ened constrictor responses to ACh and impaired relaxation
responses to isoproterenol; 2) as in atopic serum-sensitized tissues
(Fig. 1), these IL-13-induced changes in ASM responsiveness are
also prevented by pretreating the tissues with either rolipram or
the anti-Gbc blocking peptide; and 3) comparable inhibition of the
pro-asthmatic effects of IL-13 is also seen in tissues pretreated with
gallein (10 mM). Along with the above results, these observations
support the concept that activation of the Gbc subunit of Gi
protein, which elicits c-Src-induced downstream signaling via the
Ras/c-Raf1/MEK-ERK1/2 pathway [14,15], leads to PDE4
upregulation and its consequent induction of proasthmatic
changes in constrictor and relaxation responsiveness in OVA
serum- and IL-13-sensitized ASM.
Discussion
Whereas activation of the a subunits of the G proteins, Gq and
Gs, is identified as primarily responsible for mediating acute ASM
contraction and relaxation, respectively, in response to various
bronchoactive agents [1,40], signaling initiated by PTX-sensitive Gi
proteins was shown to play a critical role in mediating the
heightened constrictor and impaired relaxation responses that
typify ASM tissues sensitized under different proasthmatic condi-
tions [7–11]. The latter studies presumed that the proasthmatic role
ofPTX-sensitive Gi proteinactivation wasattributed to anobserved
increase in ASM expression of the Gai2 and Gai3 isoforms [7–9];
however, it was subsequently demonstrated that transgenic mice
Figure 4. Pulmonary inflammatory response to antigen
challenge in OVA-sensitized rabbits. Representative high magni-
fication photomicrographs (mag. 61000) demonstrating that inflam-
matory infiltrate in lung tissues (A) and BALF (B) isolated from OVA-
sensitized+challenged rabbits is mostly composed of neutrophils (N)
with lesser amounts of mononuclear macrophages (M) and rare
eosinophils (E).
doi:10.1371/journal.pone.0032078.g004
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exhibit increased ASM contractility to MCh [41]. Instead, it is now
generally recognized that most physiological processes inhibited by
PTX are mediated by the bc subunits of Gi protein, rather than the
a subunit, and that most Gbc-dependent signaling arises from Gi
protein [17,42–45]. Consistent with this concept, our present
observations demonstrated that inhibition of Gbc activation
prevented ERK1/2-dependent rolipram-sensitive changes in con-
strictor and relaxation responsiveness in rabbit ASM tissues
sensitized with OVA serum or IL-13 (Figs. 1 and 9, respectively),
and that this effect of Gbc inhibition was associated with
suppression of the upregulated PDE4 activity detected in these
sensitized tissues (Fig. 6). Moreover, inhibition of Gbc, resulting in
its impaired direct activation of c-Src and accompanying ERK1/2
activation (Fig. 7), was also found to prevent PTX-sensitive
induction of PDE4D mRNA transcripts by IL-13 in HASM cells
(Fig. 8). Finally, in concert with the well documented causal
relationship between PTX-sensitive Gbc signaling and inflamma-
tion [17–22], the present results demonstrated that, together with
abrogating in vivo airwayhyperreactivity,inhibition ofGbcsignaling
also suppressed the pulmonary inflammatory response to antigen
challenge in OVA-sensitized rabbits (Figs. 2 and 3, respectively),
and that these protective effects of Gbc inhibition were associated
with suppression of the upregulated PDE4 activity detected in the
lungs of the OVA-challenged allergic rabbits (Fig. 6A). To our
knowledge, these findings are the first to identify that Gbc signaling
leading to c-Src-induced ERK1/2-dependent upregulation of
PDE4 activity plays a decisive role in regulating the altered airway
function associated with the allergic asthmatic phenotype.
The present observations raise certain relevant considerations
regarding potential mechanisms by which Gbc signaling regulates
the proasthmatic state. In this regard, our results generally agree
with the substantial body of literature reporting that PTX-sensitive
Gbc signaling initiates critical proinflammatory events in various
cell types [17–22], including those implicated in the pathobiology
of allergic asthma. Accordingly, Gbc-induced activation of the
signaling molecules, PI3K and PLCb2/b3, was shown to be an
essential mechanism that regulates IgE-mediated degranulation by
stimulated mast cells [18,44,45], as well as the recruitment and
migration of leukocytes [17,27,46]. Moreover, it is noteworthy that
PI3K and PLCb2/b3 are also key regulators of ASM proliferation
and contractility, respectively [1,6,40], and that the latter
regulatory action may account, at least in part, for the reported
PTX-sensitive increase in ASM contractility associated with
heightened PLC-mediated inositol phosholipid signaling in ASM
isolated from allergic rabbits [47], as well as in rabbit ASM
passively sensitized with atopic asthmatic serum [5,48]. Another
mechanism relates to Gi-bc-initiated activation of MAPK
signaling, particularly that attributed to stimulation by Gi-bc of
c-Src-induced signaling via the Ras/Raf/ERK1/2 pathway [13–
15]. The present observations provide several lines of evidence
that implicate the latter Gi-bc-regulated mechanism in mediating
our observed proasthmatic changes in ASM contractility, as given
by the results demonstrating key intermediate regulatory roles for
Gi-bc, c-Src and ERK1/2 activation in mediating the upregulated
PDE4 activity associated with altered agonist responsiveness in the
sensitized ASM tissues, and induction of PDE4D transcripts by IL-
13 in HASM cells. Furthermore, our extended observations
Figure 5. Proinflammatory cellular and cytokine responses in antigen-challenged OVA-sensitized rabbits are suppressed by anti-
Gbc blocking peptide. Relative to controls, total inflammatory cell count (A) and neutrophil/macrophage cellular ratio (B), are significantly
increased in BALF samples from antigen-challenged OVA-sensitized rabbits. Correspondingly, BALF levels of INF-c are significantly reduced whereas
IL-13 levels are increased in OVA-sensitized+challenged animals. These proinflammatory indices are suppressed in BALF from sensitized rabbits that
are treated with inhaled anti-Gbc peptide prior to OVA challenge. Data are represented by bar plots depicting median and range values. Statistical
comparisons are made using the Kruskal-Wallis test. *p,0.05 based on Dunn’s post-test.
doi:10.1371/journal.pone.0032078.g005
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32078demonstrated that activation of both c-Src and ERK1/2 by IL-13
in HASM cells was suppressed by pretreatment with different
inhibitors of Gbc and, based on related co-immunoprecipitation
studies, c-Src tyrosine kinase was identified as a direct effector of
Gbc signaling (Fig. 7). Collectively, these data strongly implicate
Gi-bc signaling leading to c-Src-induced ERK1/2 activation and
its upregulation of PDE4 expression as a key signaling mechanism
that underlies the changes in airway function observed under the
Figure 6. Inhibition of Gbc-signaling prevents upregulation of PDE activity in lungs from OVA-sensitized/challenged rabbits and
passively sensitized ASM tissues. Relative to controls, PDE activity is significantly increased in lung tissues isolated from OVA-
sensitized+challenged rabbits (A) and in OVA serum-sensitized (B) and IL-13-treated (C) isolated ASM tissues. The upregulated PDE activity is
abrogated in lungs isolated from OVA-sensitized rabbits that are treated with inhaled anti-Gbc peptide prior to antigen challenge, as well as in OVA
serum- or IL-13-exposed ASM tissues that were pretreated with anti-Gbc peptide or gallein. Data are mean 6 SE values from 3–5 determinations.
Comparisons are made using two-tailed Student t-test. **p,0.01.
doi:10.1371/journal.pone.0032078.g006
Figure 7. Gbc signaling regulates IL-13-induced c-Src and ERK1/2 activation in HASM cells. (A) Immunoblots depicting IL-13-induced
transient phosphorylation of c-Src
Tyr416 and ERK1/2 in HASM cells, with peak phosphorylation detected at 10 and 30 min, respectively. (B)
Immunoblots depicting that, contrasting the lack of effect of pretreatment with MPS alone, IL-13-induced phosphorylation of c-Src
Tyr416 and ERK1/2 is
suppressed in HASM cells pretreated with either anti-Gbc peptide (20 mM) or gallein (10 mM). Additionally, in contrast to HASM cells transfected with
adeno-LacZ (i.e., negative control), IL-13-induced phosphorylation of c-Src
Tyr416 and ERK1/2 is also suppressed in HASM cells wherein Gbc signaling is
inhibited by transfection with adeno-bARK-ct. (C) Western blot depicting interaction of Gb and c-Src
Tyr416 in HASM cells stimulated with IL-13 in the
absence and presence of inhibition of Gbc activation. Following preparation of lysates from untreated and IL-13-treated (50 ng/ml610 min) HASM
cells, Gb was immunoprecipitated (IP) with anti-Gb monoclonal antibody, and subsequently immunoblotted (IB) with anti-phospho-c-Src
Tyr416
antibody (see Methods). Note, relative to untreated cells, association of Gb and c-Src
Tyr416 proteins was significantly increased in IL-13-treated HASM
cells; and formation of this protein complex was suppressed in IL-13-exposed cells that were pretreated with either anti-Gbc peptide (20 mM) or
gallein (10 mM), and also suppressed in IL-13-exposed HASM cells that were transfected with adeno-bARK-ct. The immunoblots shown in A–C are
representative from 3–4 experiments.
doi:10.1371/journal.pone.0032078.g007
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the allergic asthmatic state. Of significance, we previously
demonstrated that the same Gi-bc-driven mechanism coupled to
stimulation of the c-Src/Ras/Raf/MEK-ERK1/2 pathway is also
responsible for mediating the PDE4-induced proasthmatic chang-
es in ASM contractility observed following prolonged heterologous
or homologous b2AR-desensitization [10,11]. Given this concur-
ring evidence, along with a collection of earlier findings that the
proasthmatic changes in ASM responsiveness evoked by either
passive sensitization with human atopic asthmatic serum or
exposure to proinflammatory cytokines or rhinovirus are also
abrogated by pretreatment with PTX [7–9], the compelling
consideration is raised that signaling via the Gbc subunits of Gi
protein plays a pivotal role in regulating the induction of altered
ASM responsiveness under a variety of proasthmatic sensitizing
conditions. This provocative consideration is worthy of future
systematic investigation.
Cell-permeable peptides coupled to various cargo molecules
have been used in animals models to successfully target specific
intracellular signaling pathways implicated in disease, including in
murine models of allergic airway disease [49]. Our rationale for
using a cell permeable anti-Gbc blocking peptide, comprised of an
inert carrier MPS conjugated to the C-terminal thioredoxin-like
domain of PhLP [17], is based on previous evidence demonstrat-
ing that: 1) PhLP is endogenously expressed in a wide variety of
tissues, including lung [50], and acts as an ubiquitous inhibitor of
Gbc signaling by sequestering [50–53] or producing a conforma-
tional change in Gbc protein [53]; 2) the MPS-conjugated anti-
Gbc blocking peptide is a highly effective inhibitor of a2-
adrenergic receptor-mediated activation of MAPK [17]; and 3)
Figure 8. IL-13-induced Gi-bc signaling mediates ERK1/2-dependent upregulation of PDE4D mRNA transcripts in HASM cells. (A) IL-
13 elicits temporal increases in PDE4D mRNA expression in HASM cells, with peak induction of transcripts detected at 12 hr. A representative
experiment (B), and corresponding densitometric analysis of PDE4D mRNA expression expressed as a ratio of b-actin (C), demonstrate that IL-13
induced PDE4D transcripts at 12 hr is abrogated in HASM cells that are pretreated either with PTX, anti-Gbc blocking peptide, or inhibitors of either
MEK-ERK1/2 (U0126), c-Src tyrosine kinase (SU6656) or gallein, whereas pretreatment with inhibitors of p38 MAPK (SB202190) or JNK (SP600125) has
no effect. Data are mean 6 SE values from 4 experiments (**p,0.01).
doi:10.1371/journal.pone.0032078.g008
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the anti-Gbc blocking peptide abrogates PTX-sensitive ERK1/2
activation and its consequent induction of PDE4-mediated
changes in responsiveness in b2AR-desensitized ASM, whereas
comparable treatment with a MPS-conjugated anti-Gia3 peptide
has no effect [11]. Consistent with this evidence, our present
observations demonstrated that, together with its protective effects
in OVA serum- and IL-13-sensitized isolated ASM tissues (Figs. 1
and 9, respectively), pretreatment with aerosolized anti-Gbc
blocking peptide prevented in vivo AHR evoked by antigen
challenge in OVA-sensitized rabbits (Fig. 2). Moreover, pretreat-
ment with anti-Gbc blocking peptide also suppressed the
pulmonary inflammatory response and reversed the predominance
of IL-13 vs. IFN-c cytokine levels in the lungs of the OVA-
sensitized+challenged rabbits (Figs. 3 and 5). Of significance, these
observations, as well as those identifying that the Gbc signaling
mechanism activated in the sensitized ASM involves ERK1/2-
dependent upregulation of PDE4 activity, concur with evidence
provided in earlier in vivo studies demonstrating that: 1) inhibition
of ERK1/2 activation suppresses both the in vivo AHR and
pulmonary inflammation elicited by antigen challenge in OVA-
sensitized mice [54,55]; and 2) increased PDE4 activity plays a
decisive role in mediating both the heightened bronchoconstrictor
responsiveness and airway inflammation evoked by allergen
challenge in asthmatic subjects [28] and in animal models of
allergic asthma [29–33]. Thus, when considered in light of the
extended mechanistic observations described herein, the circum-
stantial evidence provided by the latter findings further substan-
tiate the concept that Gbc signaling associated with ERK1/2-
dependent induction of PDE4 activity is importantly involved in
mediating both the altered airway responsiveness and inflamma-
tion exhibited in the allergic asthmatic lung. In this context, it is
important to indicate that the critical role identified herein for
Gbc signaling is based on evidence demonstrating the broncho-
Figure 9. Inhibition Gbc signaling prevents rolipram-sensitive changes in agonist responsiveness in IL-13-exposed rabbit ASM
tissues. Relative to controls, ASM tissues sensitized with IL-13 (50 ng/ml624 hr) exhibit significantly increased contractility to ACh (A) and impaired
relaxation to isoproterenol (B). Inhibition of Gbc signaling by pretreatment with anti-Gbc blocking peptide or gallein, or inhibition of PDE4 activity
with rolipram, prevents IL-13-induced changes in ASM responsiveness. Data are mean 6 SD values from 5–6 experiments. ANOVA used for multiple
comparisons of mean Tmax and Rmax values. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0032078.g009
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the airway asthmatic response, and it remains to be determined
whether this treatment is also effective in reversing the asthmatic
response once manifested.
In further considering the present observations, it should be
noted that, like pretreatment with the anti-Gbc blocking peptide,
the induction of in vivo AHR and altered agonist responsiveness in
the isolated sensitized ASM tissues were also abrogated by
pretreatment with gallein, a small molecule inhibitor of Gbc
signaling [17,26,27]. Unlike the anti-Gbc blocking peptide,
however, gallein did not suppress the pulmonary inflammatory
response in OVA-sensitized+challenged rabbits (Fig. 3). While the
disparity between these inhibitors with respect to their anti-
inflammatory actions is not readily explained, one possibility
relates to potential differences in their pharmacodynamic or
pharmacokinetic properties that might influence their effects on
the effector systems that regulate AHR and inflammation. Another
reasonable explanation relates to potential differences in their
mechanisms of Gbc inhibition under the present experimental
conditions. In this regard, it has been proposed that, among the
small molecule inhibitors of Gbc signaling examined to date, each
has its distinctive spacial orientation of binding to the bioactive site
(‘‘hot spot’’) on the Gbc surface, thereby accounting for inhibition
of only specific Gbc-targeted effector interactions [17]. Accord-
ingly, in extending this concept to the present observations, it is
conceivable that gallein allows only for inhibition of those Gbc-
targeted effector interactions that regulate airway responsiveness
but not those that mediate allergic lung inflammation, although it
should be noted that gallein was found to inhibit carrageenan-
induced footpad inflammation in mice [27]. On the other hand,
by sequestering the Gbc subunit, the anti-Gbc blocking peptide is
arguably capable of relatively greater inhibition of Gbc interac-
tions with different effector targets, including those that mediate
both changes in airway responsiveness and inflammation. This
interesting possibility remains to be systematically investigated.
In evaluating the implications of the present study, it must be
emphasized that our observations pertain to studies conducted in
an in vivo rabbit model of allergic airway disease and in isolated
sensitized rabbit ASM tissues. Therefore, the extent to which these
observations relate to the human condition is open to speculation.
In this respect, it is noteworthy that our results are consistent with
recent evidence that implicates upregulated PDE4 activity in
mediating the airway responses to allergen challenge in asthmatic
individuals [28], and the induction of altered HASM function
[10,11,23,56,57]. Additionally, our data generated in the rabbit
ASM tissues are consistent with those obtained in the cultured
HASM cells, as both these experimental preparations exhibited
complementary Gbc-dependent changes in ASM function. These
included compatible effects of specific inhibitors on the Gbc-
regulated signaling events mediating IL-13-induced PDE4 expres-
sion in HASM cells (Figs. 7 and 8) and altered responsiveness in
rabbit ASM tissues (Fig. 9). Moreover, our findings regarding the
Gbc-regulated mechanism underlying the effects of IL-13 on ASM
responsiveness are consistent with those in previous reports
demonstrating that IL-13 evokes downstream ERK1/2-dependent
changes in HASM contractility [58] and intracellular calcium
mobilization [59], as well as pulmonary inflammation [60].
Regarding the latter, it should be noted that our in vivo
observations in rabbits,concur with those in previous reports that
also demonstrated a predominant neutrophilic pulmonary inflam-
matory response initially (i.e., up to 24 hours) following antigen
challenge in sensitized mice [61–63] and rabbits [64], as well as
the reported predominant neutrophilic inflammatory response
detected in BAL samples obtained hours following airway antigen
challenge in allergic asthmatic individuals [65]. In this regard,
however, it is important to note that, given the frequent
observance of eosinophilic infiltration at 24 hours after allergen
challenge in other studies in OVA-sensitized mice, consideration
must be given to other factors that may also contribute to our
observed neutrophilic response, including LPS contamination of
the administered OVA preparation. Finally, another relevant issue
is that our observed changes in constrictor and relaxant
responsiveness in the sensitized rabbit ASM tissues mimicked the
perturbations in airway function that characterize the human
asthmatic ASM phenotype, including enhanced constrictor
responsiveness to cholinergic stimulation and impaired b2AR-
mediated airway relaxation [66,67]. Thus, in view of these
considerations, we believe that the findings of the present study are
applicable, at least in part, to the human condition.
In conclusion, this study is the first to report that Gbc signaling
associated with ERK1/2 activation and upregulated PDE4 activity
plays a critical role in mediating the induction of airway
hyperresponsiveness and inflammation in a rabbit model of
allergic asthma. By identifying that Gbc signaling mediates these
key characteristic features of the airway asthmatic phenotype, the
present findings support the consideration that future interventions
targeted at modulating Gbc function may yield new approaches to
treat allergic airway disease.
Methods
Materials
All chemicals and reagents were purchased from Sigma-Aldrich
unless otherwise indicated. Human ASM (HASM) cells were
obtained from Bio Whittaker, Inc.
Animals
Thirty-five young adult (6–8 months of age) male New Zealand
White rabbits purchased from Covance were used in this study,
which was approved by the Biosafety and Animal Research
Committee of the Research Institute at Children’s Hospital of
Philadelphia.
OVA sensitization and challenge
Rabbits were actively immunized with weekly intraperitoneal
(i.p.) injections of 1 ml of an OVA-containing emulsion,
comprising 2.5 mg OVA prepared from lyophilized powder
(Grade V; $98% purity) in 1 part physiological saline and 1 part
of Alum adjuvant (Pierce), for a total of 4 injections. One week
later, similar to the approach previous described in OVA-
sensitized rabbits [68], the animals received a single inhalation
challenge of an aerosolized 7% solution of OVA in physiological
saline, delivered at a flow rate of 8 l/min over ,20 min via a
compressor nebulizer (DeVilbiss, PulmoMate) connected to an
oro-pharyngeal tube. The OVA challenges were conducted in the
absence and presence of pre-nebulization at 1 hr prior to antigen
challenge either with 0.5 mg/Kg of the inhaled glucocorticoster-
oid, budesonide (Pulmicort Respules; Astra-Zeneca), 1 mg/Kg of
a cell permeable anti-Gbc blocking peptide (AnaSpec), comprised
of a membrane permeable sequence (MPS; 15 amino acids)
conjugated to the Gbc-sequestering C-terminal domain (28 amino
acids) of phosducin-like protein [25], or 1 mg/Kg of the inert
MPS peptide alone serving as a negative-control. The blocking
Gbc peptide and control MPS aerosolized solutions were prepared
in 3 ml of physiological saline and nebulized over 15–20 min. In
separate studies, at 1 hr prior to OVA challenge, control and
OVA-sensitized rabbits were pretreated with an i.p. bolus injection
of either vehicle alone (PBS) or 30 mg/Kg of gallein [26], a
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(Acros Organics).
Measurement of in vivo bronchoconstrictor
responsiveness
At 24 hr following OVA challenge, under initial general
anesthesia with intramuscular injections of xylazine (10 mg/Kg)
and ketamine (50 mg/Kg), rabbits were tracheotomized, para-
lyzed with pancuronium bromide (0.05 mg/Kg), and mechani-
cally ventilated via an intra-tracheal cannula. The cannula was
connected to a pneumotachograph to monitor airflow and a
pressure transducer to record transthoracic pressure. As previously
described [69], the flow and pressure signals were digitized and
analyzed to determine breath-to-breath changes in respiratory
system resistance (Rrs) and dynamic compliance (Cdyn) elicited by
i.v. bolus injections of cumulatively increasing doses of MCh
(0.001–0.15 mg/Kg).
Lung histology and BALF analysis of inflammation
Following assessment of MCh responsiveness, the animals were
sacrificed with an overdose of sodium pentobarbital (100 mg/Kg)
and, similar to the approach previously described in OVA-
senstized rabbits [68] the lungs were lavaged in situ with a total of
25 ml of normal saline, delivered by slowly injecting and aspirating
five 5-ml aliquots via a pliable plastic catheter inserted into the
intra-tracheal tube. The lungs were then excised and fixed in 10%
formalin under a constant pressure of 20 cmH20. The BALF
return averaged between 67 and 79% of the total instilled volume.
Total and differential cell counts in the BALF samples were
assessed in Wright-stained cytospin preparations, with at least 500
cells counted per cytospin preparation. The levels of IL-13 and
IFN-c in the BALF supernatants were determined using ELISA
kits (R&D Systems). Paraffin-embedded 4 mM sections of lung
tissue obtained from the lower lobes of both formalin-fixed lungs
were stained with hematoxylin and eosin (H&E) and examined in
a blinded manner to assess inflammation.
Preparation and ex vivo sensitization of rabbit ASM
tissues
In separate experiments, naı ¨ve NZW rabbits were sacrificed
with sodium pentobarbital (100 mg/Kg) and the tracheae were
excised, cleaned of loose connective tissue, and the epithelium was
removed by gently scraping with a cotton-tipped applicator, as
previously described [7,24]. The isolated tracheae were divided
into equal ring segments, and each alternate segment was
incubated overnight either with vehicle alone or serum isolated
from control (non-sensitized) or OVA-sensitized rabbits at 24 hr
following OVA inhalation challenge, or with IL-13 (50 ng/ml),
both in the absence and presence of pretreatment with the anti-
Gbc blocking peptide (20 mM), MPS peptide alone (20 mM),
gallein (10 mM), the ERK1/2 inhibitor, U0126 (5 mM), or the
PDE4 inhibitor rolipram (10 mM). The tissues were exposed to
each of these treatments for ,3 hr prior to incubation with the
sera or IL-13 preparations, and the treatments were maintained
throughout the ensuing overnight period (,18 hr) leading to the
following pharmacodynamic studies.
Pharmacodynamic studies of ASM tissue responsiveness
Following incubation under the different treatment conditions,
the ASM tissue segments were placed in organ baths containing
the same concentrations of their respective pharmacological
treatments in modified Krebs-Ringer solution aerated with 5%
CO2 in O2 and attached to force transducers to monitor isometric
tension. As previously described [7–10], cholinergic contractility to
cumulatively administered acetylcholine (ACh; 10
29 to 10
23 mol/
L) was assessed and, after rinsing with fresh buffer, relaxation dose-
response curves to isoproterenol (10
29 to 10
24 mol/L) were
generated following initial half-maximal contraction of the tissues
with ACh. The constrictor and relaxation dose-response curves
were analyzed with respect to each tissue’s maximal isometric
contractile force (Tmax) to acetylcholine and maximal relaxation
response (Rmax) to isoproterenol.
Assay of cAMP PDE activity
Levels of total cAMP PDE activity were determined, as
previously described [10,11], using a colorimetric, non-radioactive
enzymatic assay (Biomol), in control and passively sensitized ASM
tissues, and in lung tissue sections isolated from the control and
OVA-sensitized rabbits under the different treatment conditions.
Following the above treatments, ASM and lung tissues sections
were immediately frozen and then stored at 280uC. At the
subsequent time of analysis, the tissue samples were thawed, then
finely minced and homogenized in ice-cold 30 mM N-2-hydro-
xyethylpiperazine-N9-ethane sulfonic acid (pH 7.4) containing
0.1% Trion X-100, and PDE activity was standardized to protein
content in the tissue samples [10,11].
Culture and treatment of ASM cells
HASM cells were grown in smooth muscle basal medium
(SmBm) supplemented with 10% FBS (BioWhittaker) and
maintained throughout in a humidified incubator containing 5%
CO2 in air at 37uC. The experimental protocols involved growing
the cells to ,95% confluence in the above medium. Thereafter, in
separate experiments, the cells were starved in unsupplemented
Ham’s F12 media for 24 hr, treated with different concentrations
and for varying durations with IL-13, and then examined for
induced changes in c-Src and ERK1/2 phosphorylation and
PDE4D mRNA expression in the absence and presence of specific
inhibitors, as described.
Transfection of ASM cells with adeno-bARK-ct
Adenovirus (adeno)-bARK-ct, an adenovirus vector encoding
the bARK1 carboxyl-terminal domain which blocks Gbc signaling
[14,15], and adeno-b-gal, an adenovirus vector expressing lacZ as
a negative control, were constructed using the AdenoX adenovirus
construction kit (BD-Clontech). Recombinant plaques were
isolated and propagated in HEK293 cells (Invitrogen), with viral
purification using the cesium chloride gradient method, and viral
titer detected by plaque assay. HASM cells were transfected with
either of the adenoviral vectors at a MOI of 100, and experiments
were conducted at 24 hr following the adenoviral transfections.
Immunoblot analysis of c-Src and ERK1/2
phosphorylation
Levels of c-Src and ERK1/2 proteins, as well as phosphorylated
c-Src at residue Tyr416 and ERK1/2 proteins, were detected by
Western blot analysis of lysates isolated from HASM cells before
and at various times after treatment with IL-13 in the absence and
presence of specific inhibitors, as described. Following protein
extraction and the addition of gel loading buffer, the extracts were
loaded on a 10% SDS-PAGE gel for immunoblotting after transfer
to a PVDF membrane. The membranes were then incubated
overnight with monoclonal mouse anti-human primary antibodies
directed against c-Src, phospho-c-Src
Tyr416, ERK and phospho-
ERK1/2 (Cell Signaling Technology), and levels were detected by
ECL after a 1-hr incubation with a 1:2,000 dilution of HRP-
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diography film. The protein band intensities were quantified by
densitometry.
Co-immunoprecipitation studies
Untreated and IL-13-treated HASM cells were prepared for co-
immunoprecipitation studies under native conditions in order to
preserve protein-protein associations. After indicated treatment,
cells were harvested and then lysed with lysis buffer. 1.5 mg of
Protein G Dynabeads (Invitrogen) were incubated with 10 mgo f
anti-Gb rabbit IgG (Millipore) and incubated for 10 min at room
temperature with rotation. Following several washes, the bound
bead/antibody complex was added to sample, mixed by pipetting,
and incubated for 2 hr at 4uC with rotation. The captured bead/
Protein G/antigen complex was then washed several times and
eluted at pH 3.0 with rotation at room temperature. The
precipitated immunocomplexes were subsequently analyzed by
immunoblotting using anti-phospho-c-Src
Tyr416 antibody.
Expression of PDE4D mRNA transcripts
After attaining confluence, the cells were starved in unsupple-
mented Ham’s F12 media for 24 hr, subsequently treated with IL-
13, and then examined under different experimental conditions for
induced changes in PDE4D mRNA expression, determined by
RT-PCR as previously described [10,11,23].
Detection of PDE4D mRNA transcripts
Total RNA was extracted from untreated and IL-13-treated
HASM cells, in the absence and presence of co-treatment with
specific inhibitors, using the TRIzol method (Invitrogen). cDNAs
were then isolated by RT-PCR using the SuperScript First Strand
Synthesis System kit from Invitrogen, with the following
oligonucleotide primer sets (Integrated DNA Technologies): for
PDE4D, 59-CGGAGATGACTTGATTGTGAC-39 (forward)
and 59-CGTTCCTGAAAAATGGTGTGC-39 (reverse); and for
b-actin, 59-GAGAAGAGCTACGAGCTGCCTGAC-39 (forward)
and 59-CGGAGTACTTGCGCTCAGGAGGAG-39 (reverse).
The reaction volume was 20 ml and cycling conditions used were
35 cycles of 30 sec denaturation at 95uC, followed by 30 sec
annealing at 60uC and elongation at 72uC for 30 sec. Ex-Tag
(Takara Biotechnology) was used as DNA polymerase.
Statistical analyses
Results are expressed as mean 6 SE values. Comparisons
between groups were made using the Student t test (2-tailed),
ANOVA with Tukey posttest analysis, and the nonparametric
Kruskal-Wallis test with Dunn’s posttest analysis, where appro-
priate. A probability of ,0.05 was considered statistically
significant. Statistical analyses were conducted by using the Prism
computer program by Graph Pad Software Inc.
Supporting Information
Figure S1 Inhibition of Gbc signaling prevents induced
changes in agonist responsiveness in OVA serum-
sensitized rabbit ASM tissues. Relative to untreated
(vehicle-exposed) controls, ASM tissues exposed to control serum
exhibit similar Tmax responses to ACh (A) and Rmax responses to
isoproterenol (B) both in the absence and presence of pre-
treatment with either MPS peptide alone or anti-Gbc blocking
peptide. By comparison, OVA serum-exposed ASM tissues exhibit
significantly increased Tmax responses (A) and reduced Rmax
responses (B) that are prevented by pre-treatment with anti-Gbc
blocking peptide, whereas pre-treatment with MPS alone has no
effect. Data are mean 6 SD values from 4–7 experiments. Treated
tissues are compared to untreated (vehicle-exposed) controls using
unpaired two-tailed Student t-test. *p,0.05; **p,0.01.
(TIF)
Figure S2 Anti-Gbc blocking peptide prevents in vivo
antigen-induced airway hyperresponsiveness in OVA-
sensitized rabbits. Relative to OVA-challenged control (non-
sensitized; n=4) rabbits, MCH-induced decreases in Cdyn are
significantly enhanced at 24 hr following antigen challenge in
OVA-sensitized rabbits (n=4). This heightened bronchoconstric-
tor responsiveness to MCh is suppressed in OVA-sensitized rabbits
that are treated either with inhaled anti-Gbc peptide (1 mg/Kg;
n-=4) or budesonide (0.5 mg/Kg; n=3) prior to antigen
challenge. Note: Data represent Cdyn responses associated with
corresponding Rrs responses shown in Fig. 2. Data are mean 6 SE
values. ANOVA used for multiple comparisons of mean Rrs
values. *p,0.05; **p,0.01.
(TIFF)
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